[go: up one dir, main page]

AR056538A1 - Formulacion acuosa hfsh - Google Patents

Formulacion acuosa hfsh

Info

Publication number
AR056538A1
AR056538A1 ARP060104208A ARP060104208A AR056538A1 AR 056538 A1 AR056538 A1 AR 056538A1 AR P060104208 A ARP060104208 A AR P060104208A AR P060104208 A ARP060104208 A AR P060104208A AR 056538 A1 AR056538 A1 AR 056538A1
Authority
AR
Argentina
Prior art keywords
hfsh
stabilized
formulation
water formulation
activity
Prior art date
Application number
ARP060104208A
Other languages
English (en)
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37899985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056538(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of AR056538A1 publication Critical patent/AR056538A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulacion acuosa de la hormona de estimulacion del folículo humano (hFSH) que se estabiliza para mantener la actividad de la hFSH durante un período de tiempo prolongado. La formulacion de la presente es una formulacion acuosa que contiene una cantidad terapéutica efectiva de hFSH estabilizado en un buffer de fosfato que contiene glicina, metionina y surfactante no-ionico, preferentemente polisorbato 20, que es capaz de mantener la actividad del hFSH durante un largo período de tiempo.
ARP060104208A 2005-09-27 2006-09-26 Formulacion acuosa hfsh AR056538A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020050089853A KR101105871B1 (ko) 2005-09-27 2005-09-27 인 난포자극호르몬의 안정한 용액 제형

Publications (1)

Publication Number Publication Date
AR056538A1 true AR056538A1 (es) 2007-10-10

Family

ID=37899985

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104208A AR056538A1 (es) 2005-09-27 2006-09-26 Formulacion acuosa hfsh

Country Status (18)

Country Link
US (2) US20110201554A1 (es)
EP (1) EP1928413B1 (es)
JP (1) JP5364374B2 (es)
KR (1) KR101105871B1 (es)
CN (1) CN101272764B (es)
AR (1) AR056538A1 (es)
AT (1) ATE466570T1 (es)
AU (1) AU2006295570B2 (es)
BR (1) BRPI0616300A2 (es)
DE (1) DE602006014175D1 (es)
ES (1) ES2345058T3 (es)
GT (1) GT200600431A (es)
PE (1) PE20070437A1 (es)
RU (1) RU2407514C2 (es)
SA (1) SA06270332B1 (es)
TR (1) TR200801968T2 (es)
TW (1) TW200735897A (es)
WO (1) WO2007037607A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2440825C2 (ru) * 2007-07-10 2012-01-27 Меди-Токс, Инк. Жидкая фармацевтическая композиция ботулинического токсина
DK2229407T3 (en) 2008-01-09 2017-02-27 Sanofi Aventis Deutschland NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE
SI2249869T1 (sl) * 2008-02-08 2012-01-31 Biogenerix Ag Tekoäśa formulacija fsh
CN103736082A (zh) 2008-10-17 2014-04-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
CA2742659C (en) * 2008-11-04 2016-09-27 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
ES2594365T3 (es) * 2010-02-12 2016-12-19 Intas Pharmaceuticals Ltd. Formulación líquida de hormona estimulante del folículo
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
ES2550357T3 (es) 2011-08-29 2015-11-06 Sanofi-Aventis Deutschland Gmbh Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
HK1223559A1 (zh) * 2013-11-12 2017-08-04 Cadila Healthcare Limited 用於促性腺激素的配方
JP6735674B2 (ja) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
RU2016132342A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
KR20160104726A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
KR102578030B1 (ko) 2014-12-12 2023-09-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 글라진／릭시세나티드 고정비 제형
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3811962A4 (en) * 2018-06-25 2022-03-16 JCR Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
CN115429751B (zh) * 2022-09-21 2023-11-17 景泽生物医药(合肥)股份有限公司 一种人重组卵泡刺激素注射剂及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
RU2062619C1 (ru) * 1994-02-08 1996-06-27 Курский сельскохозяйственный институт им.проф.И.И.Иванова Способ получения препарата фолликулостимулирующего гормона из аденогипофизов животных
PT814841E (pt) * 1995-03-21 2002-03-28 Applied Research Systems Formulacoes liquidas de hcg
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP4719357B2 (ja) * 1998-07-23 2011-07-06 アレス トレイディング ソシエテ アノニム Ｆｓｈ及びｆｓｈ変異体の製剤、製品及び方法
DE60005806T2 (de) * 1999-04-08 2004-08-05 Genentech, Inc., South San Francisco Zusammensetzung auf basis gegensätzlich geladener polypeptide
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
CN1292655C (zh) * 2001-11-08 2007-01-03 蛋白质设计实验室股份有限公司 IgG抗体稳定的液态药物制剂
JP2005517012A (ja) * 2002-02-08 2005-06-09 アルカーメス コントロールド セラピューティクス，インコーポレイテッド 持続放出のためのポリマーベース組成物
US20050232899A1 (en) * 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
CN1195069C (zh) * 2002-11-28 2005-03-30 南京医科大学 人卵泡刺激素β亚基单克隆抗体的制备方法
CA2518903C (en) * 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
EP1909831A4 (en) * 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
SI2249869T1 (sl) * 2008-02-08 2012-01-31 Biogenerix Ag Tekoäśa formulacija fsh

Also Published As

Publication number Publication date
BRPI0616300A2 (pt) 2011-06-14
US20160243242A1 (en) 2016-08-25
ES2345058T3 (es) 2010-09-14
JP5364374B2 (ja) 2013-12-11
GT200600431A (es) 2007-08-28
PE20070437A1 (es) 2007-04-26
KR20070035232A (ko) 2007-03-30
CN101272764A (zh) 2008-09-24
RU2008111632A (ru) 2009-10-10
SA06270332B1 (ar) 2011-01-15
EP1928413B1 (en) 2010-05-05
TW200735897A (en) 2007-10-01
DE602006014175D1 (de) 2010-06-17
AU2006295570B2 (en) 2012-08-30
CN101272764B (zh) 2011-05-04
AU2006295570A1 (en) 2007-04-05
US20110201554A1 (en) 2011-08-18
KR101105871B1 (ko) 2012-01-16
WO2007037607A1 (en) 2007-04-05
RU2407514C2 (ru) 2010-12-27
EP1928413A1 (en) 2008-06-11
EP1928413A4 (en) 2008-12-03
TR200801968T2 (tr) 2008-06-23
JP2009509953A (ja) 2009-03-12
ATE466570T1 (de) 2010-05-15

Similar Documents

Publication Publication Date Title
AR056538A1 (es) Formulacion acuosa hfsh
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
MX2010004388A (es) Formulaciones de hormona paratiroidea y usos de las mismas.
AR049590A1 (es) Composiciones de limpieza humectantes suaves
CL2017002488A1 (es) Formulación farmacéutica estable para administración intratecal que comprende una proteína arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que además puede contener un agente estabilizante; contenedor que comprende dicha formulación; uso para tratar la enfermedad leucodistrofia metacrómatica (mld). (divisional solicitud 3654-2012)
MX2010004169A (es) Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
AR042815A1 (es) Dispositivo de suministro de agente activo que tiene miembros compuestos
MX2009003569A (es) Metodo de administracion de farmacos para la proteina anabolica osea.
CL2004000931A1 (es) Pelicula consumible adaptada para adherirse y disolverse en la cavidad bucal que comprende un almidon modificado y un agente farmaceuticamente activo.
AR047949A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial
AR069020A1 (es) Composicion para el cuidado del cabello
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
CL2009001680A1 (es) Composiciones agroquimicas que comprenden a)metconazol o una sal del mismo y b)un acido carboxilico alifatico de cadena lineal o ramificada, saturado o no saturado y donde la relacion molar de (b) respecto de (a) es superior a 1
PL357132A1 (en) Stable, nasally, orally or sublingually applicable pharmaceutical preparation
BR0304298A (pt) Composição contendo um ácido orgânico cosmeticamente ativo e um produto de legume
ES2895910T3 (es) Composiciones multifásicas
ATE326947T1 (de) Thixotropes nasenspray
DE60308718D1 (de) 3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff and pharmaceutische formulatierungen davon
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
NO20044723L (no) Injiserbare veterinaermedisinske sammensetninger for sma dyr
GT200300004A (es) Sales estables del acido o-acetilsalicilico con aminoacidos basicos ii
AR045392A1 (es) Composiciones para el tratamiento del cabello
DK1585513T3 (da) Anvendelse af docosahexaensyre som aktivt stof til behandling af lipodystrofi
AR067047A1 (es) Formulaciones acuosas de acetaminofen para inyeccion.
AR044563A1 (es) Solucion acuosa de olanexidina, metodo para preparar la solucion acuosa y su uso como desinfectante y esterilizante

Legal Events

Date Code Title Description
FC Refusal